Posted by Michael Wonder on 13 Jul 2024
FDA grants fast track designation to 9MW2821 for the treatment of patients with locally advanced or metastatic nectin-4 positive TNBC
12 July 2024 - Mabwell announces that its self-developed novel nectin-4-targeting ADC (9MW2821) has been granted fast track designation by the US FDA for the treatment of locally advanced or metastatic nectin-4 positive triple negative breast cancer.
9MW2821 has received multiple regulatory designations from the FDA within just 6 months.
